Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression levels of genes of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 3 days after antigenic re-challenge

ABSTRACT: Expression levels of genes of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 3 days after antigenic re-challenge

PROVIDER: PRJNA420034 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6326170_1.fastq.gz	Fastqsanger.gz
	SRR6326170_2.fastq.gz	Fastqsanger.gz
	SRR6326180_1.fastq.gz	Fastqsanger.gz
	SRR6326180_2.fastq.gz	Fastqsanger.gz
	SRR6326161_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Expression levels of genes of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 3 days after antigenic re-challenge

Project description:We performed RNA-Seq and compared expression levels of genes of reactivated LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen of LCMV.GP61-80 primed C57BL/6 mice. Cells were isolated 3 days after antigenic re-challenge

2018-01-15 | GSE107413 | GEO

Whole-transcriptome profiling of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 60 days after last immunization [RNA-seq]

Project description:To udnderstand the tissue-resident features of antigen-specific memory T cells of the bone marrow and spleen, we performed RNA-Seq and compared expression levels of genes of resting LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen of LCMV.GP61-80 primed C57BL/6 mice.

2019-02-11 | GSE124794 | GEO

Janthinobacterium sp. 77 strain:77

Project description:Janthinobacterium sp. 77 strain:77 Genome sequencing

| PRJNA442011 | ENA

Methylobacterium sp. 77 strain:77

Project description:Methylobacterium sp. 77 strain:77 Genome sequencing and assembly

| PRJNA165569 | ENA

Project description:bm Raw sequence reads

| PRJNA886391 | ENA

Next Generation sequencing and quantitative transcriptomic analysis in -77+/+ and -77-/- erythroid precursors

Project description:Gene expression profiles of sorted erythroid precursors from E14.5 wild-type (WT) and -77 enhancer knockout (-77-/-) mouse fetal liver were generated by next generation sequencing, in triplicate, using Illumina Hiseq2500 (1X50). We showed that the Gata2 -77 enhancer generated the vital erythroid precursor Burst Forming Unit-Erythroid by two mechanisms, GATA-1 upregulation to establish the erythroid transcriptome and GATA-2-dependent, GATA-1-independent transcriptional regulation.

2017-09-19 | GSE96059 | GEO

Mature IgM+ plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge

Project description:Dogma holds that plasma cells (PC), as opposed to B cells, cannot bind antigen (Ag) because they have switched from expression of membrane-bound immunoglobulins that constitute the B cell Ag receptor (BCR) to production of the secreted form of immunoglobulins. We have compared the phenotypical and functional attributes of PC generated by the T-cell-dependent and T-cell-independent forms of the hapten NP. We unexpectedly found that the nature of the secreted Ig isotype rather than the chemical structure of the immunizing Ag defines two functionally distinct populations of PC. Fully mature IgM-expressing bone marrow PC retain expression of a functional BCR while their IgG+ counterparts do not. We show that Ag boost modifies the gene expression profile of IgM+ PC and initiates a cytokine production program, characterized by upregulation of CCL5 and IL-10. Our results demonstrate that IgM-expressing PC can sense Ag and acquire competence for cytokine production upon antigenic challenge.

2016-11-01 | GSE80216 | GEO

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Project description:For patients with unresectable colorectal cancer liver metastases, preclinical studies have shown that after the resistance of cetuximab, the treatment sensitivity can be restored by stopping cetuximab for a period of time. This is called the cetuximab re-challenge. And the circulating tumor DNA (ctDNA) test is reported a biomarker for the efficacy of cetuximab rechallenge. However, there is still no randomized controlled trial for verification. This study aims at patients after the first-line treatment of cetuximab has progressed. After the second-line non-cetuximab treatment has progressed, the effects of re-application of combined with cetuximab and chemotherapy alone are compared to verify the re-challenge effect.

| 2348546 | ecrin-mdr-crc

antigenic KPC model_bulk pancreas RNASeq

Project description:antigenic KPC model_bulk pancreas RNASeq

| PRJNA544120 | ENA

Whole-transcriptome profiling of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 60 days after last immunization [RNA-seq]

Project description:Whole-transcriptome profiling of LCMV.GP66-77 specific CD4 T cells isolated from bone marrow (BM) and spleen, 60 days after last immunization [RNA-seq]

| PRJNA513500 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data